个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Concomitant SBRT and EGFR-TKI Versus EGFR-TKI Alone for Oligometastatic NSCLC: A Multicenter, Randomized Phase II Study

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Peng, P.[1] * ; Chen, Y.[1,2] ; Han, G.[3] ; Meng, R.[4] ; Zhang, S.[4] ; Liao, Z.[5] ; Zhang, Y.[1] ; Gong, J.[1] ; Xiao, C.[3] ; Liu, X.[3] ; Zhang, P.[1] ; Zhang, L.[1] ; Xia, S.[1] ; Chu, Q.[1] ; Chen, Y.[1,2] ; Zhang, L.[1] ;
单位： [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Oncol, Tongji Hosp, Wuhan, Hubei, Peoples R China [2]Wuhan Univ, Renmin Hosp, Dept Clin Oncol, Wuhan, Hubei, Peoples R China [3]Hubei Canc Hosp, Dept Radiat Oncol, Wuhan, Hubei, Peoples R China [4]Huazhong Univ Sci & Technol, Tongji Med Coll, Canc Ctr, Union Hosp, Wuhan, Hubei, Peoples R China [5]Wuhan Univ, Zhongnan Hosp, Dept Radiat & Med Oncol, Wuhan, Hubei, Peoples R China
出处：
DOI： 10.1016/j.jtho.2019.08.499
ISSN：

关键词： oligometastatic NSCLC SBRT TKI

语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2018]版：
大类 | 1 区 医学
小类 | 2 区 肿瘤学 2 区 呼吸系统
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2017]版：
Q1 RESPIRATORY SYSTEM Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者：
第一作者单位： [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Oncol, Tongji Hosp, Wuhan, Hubei, Peoples R China
推荐引用方式(GB/T 7714)：
Peng P.,Chen Y.,Han G.,et al.Concomitant SBRT and EGFR-TKI Versus EGFR-TKI Alone for Oligometastatic NSCLC: A Multicenter, Randomized Phase II Study[J].JOURNAL OF THORACIC ONCOLOGY.2019,14(10):S250-S251.doi:10.1016/j.jtho.2019.08.499.
APA：
Peng, P.,Chen, Y.,Han, G.,Meng, R.,Zhang, S....&Zhang, L..(2019).Concomitant SBRT and EGFR-TKI Versus EGFR-TKI Alone for Oligometastatic NSCLC: A Multicenter, Randomized Phase II Study.JOURNAL OF THORACIC ONCOLOGY,14,(10)
MLA：
Peng, P.,et al."Concomitant SBRT and EGFR-TKI Versus EGFR-TKI Alone for Oligometastatic NSCLC: A Multicenter, Randomized Phase II Study".JOURNAL OF THORACIC ONCOLOGY 14..10(2019):S250-S251

相关文献

[1]Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR-Mutant NSCLC pts with Oligometastatic or Oligoprogressive Liver Metastases [2]EGFR-TKIs plus Stereotactic Body Radiation Therapy (SBRT) for Stage IV Non-small Cell Lung Cancer (NSCLC): a prospective, multicenter, randomized, controlled phase II study [3]EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases [4]Sintilimab, SBRT and GM-CSF for metastatic NSCLC: A prospective, multicenter, phase II trial [5]PD-1 Monoclonal Antibody Plus Apatinib Combined With SBRT in HCC With PVTT [6]SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC [7]Genomic Origin and EGFR-TKI Efficacy of Pulmonary Adenosquamous Carcinoma [8]Sintilimab, SBRT and GM-CSF for Metastatic NSCLC: A Prospective, Multicenter, Phase II Trial [9]Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma [10]Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

资源点击量：426 今日访问量：0 总访问量：408 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）